ZY
Income statement / Annual
Last year (2021), Zymergen Inc.'s total revenue was $16.74 M,
an increase of 26.04% from the previous year.
In 2021, Zymergen Inc.'s net income was -$361.79 M.
See Zymergen Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$16.74 M
|
$13.28 M
|
$15.42 M
|
| Cost of Revenue |
$69.72 M |
$84.82 M |
$102.64 M |
| Gross Profit |
-$52.98 M |
-$71.53 M |
-$87.22 M |
| Gross Profit Ratio |
-3.16 |
-5.38 |
-5.66 |
| Research and Development
Expenses |
$159.12 M
|
$90.85 M
|
$50.72 M
|
| General & Administrative
Expenses |
$83.01 M
|
$60.08 M
|
$61.25 M
|
| Selling & Marketing
Expenses |
$23.65 M
|
$18.63 M
|
$24.14 M
|
| Selling, General &
Administrative Expenses |
$106.66 M
|
$78.70 M
|
$85.39 M
|
| Other Expenses |
$175.51 M |
$0.00 |
$0.00 |
| Operating Expenses |
$265.78 M |
$169.56 M |
$136.10 M |
| Cost And Expenses |
$335.50 M |
$254.37 M |
$238.74 M |
| Interest Income |
$64,000.00 |
$492,000.00 |
$4.92 M |
| Interest Expense |
$14.71 M |
$10.96 M |
$2.94 M |
| Depreciation &
Amortization |
$20.70 M
|
$18.71 M
|
$15.20 M
|
| EBITDA |
-$326.33 M
|
-$232.58 M
|
-$218.65 M
|
| EBITDA Ratio |
-19.49 |
-17.51 |
-14.18 |
| Operating Income Ratio
|
-20.73
|
-18.15
|
-15.38
|
| Total Other
Income/Expenses Net |
-$14.71 M
|
-$21.15 M
|
$318,000.00
|
| Income Before Tax |
-$361.73 M |
-$262.24 M |
-$236.80 M |
| Income Before Tax Ratio
|
-21.61
|
-19.74
|
-15.36
|
| Income Tax Expense |
$51,000.00 |
-$49,000.00 |
$8,000.00 |
| Net Income |
-$361.79 M |
-$262.19 M |
-$236.80 M |
| Net Income Ratio |
-21.61 |
-19.74 |
-15.36 |
| EPS |
-4.87 |
-2.68 |
-2.42 |
| EPS Diluted |
-4.87 |
-2.68 |
-2.42 |
| Weighted Average Shares
Out |
$74.31 M
|
$97.94 M
|
$97.94 M
|
| Weighted Average Shares
Out Diluted |
$74.31 M
|
$97.94 M
|
$97.94 M
|
| Link |
|
|
|
